Inspiremd Stock Price, News & Analysis

InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for five new non-executive employees. The Compensation Committee approved a total of 88,324 shares of restricted stock under the company's 2024 Inducement Plan.

The grants, made outside the company's 2021 Equity Incentive Plan, have a grant date of September 24, 2025. The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.

InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, has appointed Dan Dearen to its Board of Directors. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors.

Dearen's notable achievements include serving as President, co-Founder, and CFO of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024. He also held key positions at Vessix Vascular (acquired by Boston Scientific for $425 million) and currently serves on the boards of JenaValve Technology and BetaBionics.

This appointment comes at a strategic time as InspireMD continues its U.S. commercial launch of CGuard Prime, following FDA approval.

InspireMD (NASDAQ:NSPR), the developer of the CGuard® Prime carotid stent system for stroke prevention, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 10:00am ET.

Investors can access both the live audio webcast and replay of the presentation through the company's website investor calendar section at inspiremd.com/investors/investor-calendar/.

Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.

Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.

InspireMD (Nasdaq: NSPR) reported Q2 2025 financial results, marking a transformative period highlighted by the FDA approval and U.S. commercial launch of their CGuard Prime carotid stent system. The company secured $58 million in gross proceeds through equity private placement and warrant exercises.

Q2 2025 revenue increased 2.3% to $1.78 million, while operating expenses rose 55.2% to $13.33 million due to U.S. sales force expansion. The company reported a net loss of $13.15 million ($0.26 per share). Cash position stood at $19.37 million as of June 30, 2025. Additional milestones include CE Mark approval for CGuard Prime EPS and key leadership appointments.

InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, has appointed Raymond W. Cohen to its Board of Directors. Cohen brings over 40 years of medical technology leadership experience, most notably as CEO of Axonics, which he led to a $3.7 billion acquisition by Boston Scientific in 2024.

Cohen's appointment comes at a strategic time following the PMA approval of InspireMD's CGuard Prime carotid stent system. His extensive experience includes leading SoniVie Ltd. (acquired for $600 million), and serving as CEO of Vessix Vascular and Cardiac Science. The company aims to leverage Cohen's expertise in scaling commercial operations as it focuses on the U.S. market launch of its stroke prevention technology.

InspireMD (NASDAQ: NSPR) has secured combined financings of $58 million through a private placement (PIPE) and warrant exercises. The PIPE financing, led by OrbiMed and Marshall Wace, raised $40.1 million by issuing 16,556,184 shares at $2.42 per share. An additional $17.9 million was generated through warrant exercises triggered by FDA approval of the company's CGuard Prime carotid stent system.

The funding will support the U.S. commercial launch of CGuard Prime, which recently received FDA premarket application approval (PMA). The company benefits from a favorable reimbursement environment, including a national coverage decision for carotid stenting. BofA Securities served as the exclusive placement agent for the PIPE transaction, which is expected to close by August 1, 2025.

InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, will release its Q2 2025 financial results on Tuesday, August 5, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights.

Investors can access the earnings call by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international). A webcast will be available on InspireMD's website, and a replay will be archived for later viewing.

InspireMD (Nasdaq: NSPR) has officially launched its CGuard Prime carotid stent system in the U.S. market following FDA PMA approval. The innovative device, designed for stroke prevention, features three key advantages: a dual layer design with the largest open-cell frame and smallest mesh pore size, a MicroNet™ bio-stable mesh made from 20 μm PET, and SmartFit™ technology for precise vessel wall apposition.

The company has already achieved double-digit market share across 30+ countries and has assembled an experienced commercial team for the U.S. launch. Dr. D. Chris Metzger, System Vascular Chief at OhioHealth, highlighted the system's enhanced embolic protection and deliverability, while Ballad Health's involvement demonstrates the technology's progression from clinical trials to commercial use.